30.8 C
Vientiane
Friday, June 6, 2025
spot_img
Home Blog Page 517

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

SHANGHAI, April 2, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with or without antitumor therapies, for the treatment of advanced solid tumors.

7MW3711 is developed by Mabwell’s Interchain-Disulfide Drug Conjugate (IDDC™) platform and is pharmaceutical characterized as stable structure, homogeneous composition, high purity, and it is suitable for industrial scale-up. The approved phase Ib/II clinical trial aims to evaluate the safety, tolerability, preliminary efficacy and pharmacokinetic profile of 7MW3711 in combination with a PD-1 inhibitor, with or without antitumor therapies, in patients with advanced solid tumors. Previously, 7MW3711 has been approved for clinical studies in advanced solid tumors by the NMPA and the FDA, respectively, and was granted orphan drug designation (ODD) by the FDA for the treatment of small cell lung cancer.

About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 16 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for market approval, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for “Significant New Drugs Development”, 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects. Mabwell’s Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is “Explore Life, Benefit Health” and our vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.

Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

 

Superconductors made by Faraday Factory helped to achieve first plasma in a levitated dipole fusion prototype

Faraday Factory Japan, the world’s largest manufacturer of high-temperature superconductors, announces that its superconductor tape was successfully used to build magnets for a novel fusion prototype that has recently achieved first plasma

TOKYO, April 2, 2025 /PRNewswire/ — Faraday Factory Japan supplied high temperature superconductor tape for magnet coils used in OpenStar’s magnet prototype with a unique engineering design. On its path to proving the levitated dipole technology, New Zealand-based fusion power developer OpenStar Technologies built a machine with a battery-powered HTS dipole magnet inside. This superconducting magnet named ‘Junior’, suspended with a magnetic force within a vacuum chamber, maintains an external plasma, which will serve as a media for the fusion reaction to happen. The levitated dipole design eases many of the engineering constraints but requires that its energy source operates onboard the magnet, unattached to the walls of the vacuum chamber.

Fusion machine made by OpenStar Technologies (NZ) achieves first plasma in October 2024 with a magnet made with high temperature superconductor tape supplied by Faraday Factory (JP)
Fusion machine made by OpenStar Technologies (NZ) achieves first plasma in October 2024 with a magnet made with high temperature superconductor tape supplied by Faraday Factory (JP)

In October 2024, OpenStar Technologies produced a 300,000°C plasma inside its demonstration device and successfully sustained it for 20 seconds.

Fusion power is a long-sought technology with the potential to decouple energy from resource constraints. Engineering barriers like creating strong magnetic fields confining extremely hot plasma must be overcome in order to enable commercially viable power generation technology. Magnet coils made from high temperature superconductors have proven to be the enabling game-changer for this tough-tech. It’s important to note that the development of OpenStar Technologies‘ first machine took place at an extraordinary fast pace of 2 years on a budget of only $10 million. This important technology validation step was made possible for many reasons, last but not least due to availability of high temperature superconductor tape.

Faraday Factory Japan has been offering market-leading high temperature superconductor products since its start in 2011. A new factory in Zama (Kanagawa, Japan) has an annual output of over 2,500 km, contributing to keeping the fusion industry on a fast track to abundant, reliable and clean fusion power.

Faraday Factory Japan is the world’s largest manufacturer of high-temperature superconductors. The company started to operate its new production facility in 2024.

OpenStar Technologies was founded in 2021 in Wellington, New Zealand. Founder and CEO, Ratu Mataira, assembled an elite founding team to revive the levitated dipole concept. OpenStar has since achieved significant milestones in rapid time.

 

Synechron Launches Cybersecurity AI Accelerators, Strengthening Enterprise Security

SYDNEY, April 2, 2025 /PRNewswire/ — Synechron, a leading global digital transformation consulting firm, today announced the launch of Synechron CyberAI accelerators program. This suite of four AI-driven solutions enhances enterprise security, streamlines compliance, and reduces risk exposure through automation and intelligence. 

Synechron’s 14th accelerator program includes: 

  • RiskControl.AI: Automates IT risk management, offering real-time control assessments and compliance insights
  • AppSec.AI: Provides a unified view of security vulnerabilities, streamlining risk prioritization and remediation
  • Resolve.AI: Categorizes and manages application and security incidents, providing prioritized responses and system reliability
  • Validate.AI: Safeguards GenAI models by implementing industry guardrails including detecting prompt injection, data and privacy leakage, and insecure output handling

“We identified a gap where businesses struggled to keep pace with the speed and complexity of cyber threats,” said Faisal Husain, Co-founder and CEO of Synechron. “Synechron CyberAI fills that need by delivering solutions that scale, adapt, and strengthen defenses through AI-powered automation.” 

Synechron CyberAI is the latest FinLabs accelerator program, which is a solutions suite that will empower large organizations to stay ahead of emerging threats, delivering AI-powered security at a time when both proactive defense and efficiency are critical to businesses. 

“Synechron CyberAI aims to give companies the tools to anticipate and address security challenges before they become crises,” said Sandeep Kumar, Synechron’s head of FinLabs. “We provide a framework for businesses to integrate AI into their security strategies, which in turn makes risk management more proactive and effective.” 

About Synechron:

At Synechron, we use the power of digital transformation to drive positive change. As a global technology consulting firm, we blend creativity with innovation to deliver top-tier solutions. Synechron’s technologies and strategies span artificial intelligence, cybersecurity, consulting, digital, cloud and devops, data, and software engineering. Through our research and development arm, FinLabs, we build award-winning solutions adaptable to the needs of our clients. Synechron has a global workforce of more than 14,500 employees in more than 60 offices around the world. Discover more on our website or LinkedIn. 

For more information, please contact: 

Rashmi Joshi,
Global PR & Media Relations, Synechron 
(+91) 9560694654 
Rashmi.Joshi@synechron.com 

 

Makera Unveils Next-Gen CAM Software on April 2, 2025: Democratizing Digital Fabrication for Global Makers

Innovative CAM Software Democratizes CNC Milling for Makers of All Levels

MIDDLETOWN, Del., April 2, 2025 /PRNewswire/ — Makera, the pioneer of intelligent desktop CNC solutions, today announced the new release of its next-generation Makera CAM software, redefining accessibility in digital fabrication. Building on February’s successful launch, this latest version introduces a range of enhanced features and refined capabilities, all designed to streamline and elevate the design-to-manufacturing process for makers of all skill levels. The new release will be showcased in a YouTube Live event on April 2nd at 6 PM ET.


Building a Raspberry Pi Game Console with Makera CAM & Carvera

A New Era for Makers

It is an exciting time to be a maker. In today’s world, the “DIYer” and maker enthusiast is spoiled for choice when it comes to finding tools and equipment to bring into their personal creative spaces. However, until now, one key tool has remained cumbersome to learn, difficult to access, and often expensive—CAM software. Fortunately, that’s all about to change.

Understanding CAM Software

CAM (Computer-Aided Manufacturing) software is essential for preparing designs for production using a CNC (Computer Numerical Control) machine. Whether it’s 3D printers, laser cutters, milling machines, routers, or lathes, each relies on some form of CAM software to function. Traditionally, CAM software has been difficult to master and prohibitively costly due to high subscription fees, limiting accessibility for many makers.

Introducing Makera CAM – A Game Changer

Known for making the smartest, safest, and most versatile desktop CNC Milling machines, Makera released the 3D milling version of Makera CAM during a YouTube Live event on February 26th. Makera CAM is different, not only because it’s free but also because it’s designed to be simple and easy to learn. Getting up to speed with any new program can be a challenge, but Makera CAM’s interface and tools have been designed for makers, and makers who may not have a lot of prior milling experience in particular. Accompanied by extensive tutorials, a wide range of example projects, and a rapidly growing maker community, Makera CAM is amazingly simple with intuitive tools suitable for bringing your ideas to life.

Power and Versatility for All Makers

That’s not to say an advanced user wouldn’t be able to find success with Makera CAM either. Another one of Makera CAM’s game changing features is that you can work with an extensive variety of design types, from 2D vector files to 3D models, 3D meshes, even image files or PCBs. This accompanies Makera’s versatile CNC milling machines which can manufacture 2D or 3D parts using a wide range of material types, from woods to metals and even composites like carbon fiber or printed circuit boards.

Multi-Axis and Multi-Technology Support

Makera CAM can also prepare designs for manufacturing in a traditional 3-axis layout, or for when machines are configured with a 4th-axis module that allows for truly unique geometries to be machined too. And because Makera CAM has some simple CAD features built-in, and can work with anything from an outline to an image, you can also prepare designs for production using laser engraving technology as well as milling operations…all in a single program!

Democratizing Manufacturing Technology

In a market where traditional CAM software has long been marked by steep learning curves and high subscription fees, Makera CAM breaks the mold. Currently free for all Carvera’s users, the new Makera CAM software empowers DIY enthusiasts and professional makers alike by providing an intuitive, user-friendly interface backed by comprehensive tutorials and a supportive community.

“With this innovative release of Makera CAM, we are committed to removing the barriers that have historically hindered makers from realizing their creative visions,” said Josh, the Makera CEO. “Our upgraded Makera CAM software not only simplifies complex manufacturing processes but also integrates a wide array of functionalities that cater to both beginners and advanced users.”

The Future of Making Is Here

It’s truly a great time to be a maker—some might even call it the era of makers. With tools like Makera CAM and the Carvera Desktop CNC, anyone can turn their ideas into reality.

Join the Upcoming Live Event

Makera, Inc. invites makers, enthusiasts, and industry professionals to join its YouTube live event on April 2, 2025, at 6 PM ET, featuring: 

  • Live CNC machining demonstrations
  • Community project showcases
  • Exclusive Q&A with engineering leads
  • Lucky draws with amazing gifts

About Makera, Inc.

Makera, Inc. is a pioneer in the field of desktop CNC milling technology, dedicated to empowering makers with safe, smart, and versatile manufacturing solutions. By continuously innovating and reducing barriers to creative production, Makera fuels a global community of makers, transforming ideas into reality.

Media Contact:
monica@makera.com
www.makera.com

Yijiahe Showcases Embodied AI Robots at CCE 2025 in Shanghai

SHANGHAI, April 2, 2025 /PRNewswire/ — At the 2025 Shanghai International Cleaning Technology and Equipment Expo (CCE 2025),Yijiahe Technology Co., Ltd., a publicly traded company and a leader in the Chinese robotics market, unveiled its latest developments, including sophisticated embodied AI robots and advanced intelligent cleaning solutions, captivating widespread attention among buyers and visitors.

(left to right): Yijiahe's commercial cleaning robots J20, J40, and J30
(left to right): Yijiahe’s commercial cleaning robots J20, J40, and J30

With years of accumulated industry experience and expertise, Yijiahe has engineered two proprietary core technologies for its humanoid robots: the Smart Cerebellum Controller (enabling precise motion control, dynamic balance, and navigation for lifelike movements) and the Bionic Tactile Skin (utilizing flexible electronics and haptic feedback to accurately sense pressure and texture, significantly enhancing human-robot interaction).

At the event, Shuichi Hashimoto, General Manager of MM International Inc., Yijiahe’s partner in Japan, delivered a keynote address titled Cleaning 3.0. He described the challenges facing Japan’s cleaning industry – aging demographics and labor shortages driving up traditional workforce costs – and how the collaboration with Yijiahe has boosted the success rates of their projects through the commercial availability of their J20, J30, and J40 series cleaning robots in the Japanese market.

Yijiahe is also expanding into home eldercare solutions, positioning its embodied AI humanoids to capture growth opportunities in the burgeoning trillion-dollar industry amid accelerating aging trends.

 

YASH Technologies, a global consulting firm, achieves the coveted Salesforce Summit (Platinum) Partner status

A Landmark Achievement in Service Delivery Excellence – YASH Technologies Joins the Top Tier of Salesforce Partners

EAST MOLINE, Ill., April 2, 2025 /PRNewswire/ — YASH Technologies, a leading global technology services and systems integration company, is proud to announce its elevation to Summit (Platinum) Partner status within the Salesforce Partner Program. This prestigious milestone positions the organization among the top tier of Salesforce Consulting partners worldwide.

YASH Technologies achieves the coveted Salesforce Summit (Platinum) Partner status
YASH Technologies achieves the coveted Salesforce Summit (Platinum) Partner status

“This recognition exemplifies YASH’s ability to align its consulting solutions with Salesforce’s Customer 360 vision, led by Agentforce innovation to empower enterprises in their digital transformation journey,” stated Ravi Dhote, VP and Salesforce Business Head at YASH Technologies. “At YASH, we prioritize building impactful and customer-focused solutions that maximize value with higher ROI for our Customers. Our elevation to Summit Partner status underscores our deep commitment to customer success and our ability to develop and deploy digital capabilities rapidly.”

Each Salesforce project undertaken by YASH is meticulously measured against partner performance scores and customer satisfaction (CSAT) surveys, reaffirming its dedication to quality and innovation. With an AI-led customer-first approach and consistent focus on service excellence, YASH Salesforce’s practice has successfully handled challenges, adapted to evolving client needs, and delivered meaningful business results, contributing to this significant recognition.

Nitin Gupta, Global Head of Digital & Infrastructure Services at YASH Technologies, emphasized the company’s forward-thinking approach: “Artificial Intelligence is fundamentally reshaping how businesses engage with customers and drive operational efficiency. At YASH, we are at the forefront of integrating Agentic AI into our Enterprise solutions to deliver intelligent, responsive, and scalable customer experiences. The summit-level recognition validates our ability to harness these innovations and accelerate digital transformation for enterprises globally. We are excited to continue leveraging our deep Salesforce capabilities to create meaningful business impact.”

As a Summit Partner, YASH Technologies will continue to invest and continue to build deep expertise in the Salesforce platform that addresses evolving business needs. YASH as one of the key sponsors for the upcoming Agentforce Events (NYC, Dubai, and Mumbai), will showcase its Agentforce offering with ‘Live Autonomous Agent’ spanning across Sales, Service, and Marketing functions.

About YASH Technologies:

YASH Technologies focuses on enabling its customers to reimagine their businesses and drive outcome-centric Digital Transformation. As a leading technology integrator and outsourcing partner for large and fast-growing global customers, YASH leverages strategic advisory, technology consulting, and flexible business models to help customers realize value from their digital journey while fostering innovation. YASH’s customer-centric & consultative engagement framework integrates specialized domain & consulting capabilities with proprietary methodologies and digital solutions to provide secure application, cloud, infrastructure, engineering, and end-user-focused services for discerning customers globally. Headquartered in the US, with delivery and sales centers globally, YASH serves its customers across six continents. YASH is CMMI DEV V2.0 Level 5 & an ISO 9001:2015, ISO 27001:2013, and ISO 20000:2011 certified organization.

For more information, please visit www.yash.com or email info@yash.com.

 

 

 

NCCN 2025 Annual Conference Illustrates the Critical Impact of Cancer Research on Improving Lives

The National Comprehensive Cancer Network celebrated its 30th anniversary with a series of presentations on cancer care practice changes—in both treatment and administration—plus new research, and other changes for the oncology workforce and the patients they serve.

ORLANDO, Fla., April 2, 2025 /PRNewswire/ — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—celebrated 30 years of helping people with cancer to live better lives during the NCCN 2025 Annual Conference, March 28-30 in Orlando, Florida. The yearly event brings together leading minds and subject matter experts in front of a multidisciplinary audience to share the latest recommendations for cancer treatment and prevention.

The NCCN Annual Conference brings together leading minds and subject matter experts in front of a multidisciplinary audience to share the latest recommendations for cancer treatment and prevention. Learn more at NCCN.org/conference
The NCCN Annual Conference brings together leading minds and subject matter experts in front of a multidisciplinary audience to share the latest recommendations for cancer treatment and prevention. Learn more at NCCN.org/conference

“We are proud to honor our founders’ vision of sharing evidence-based, expert consensus-driven recommendations through clinical practice guidelines to improve cancer care,” said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. “Over the years our organization has responded to a rapidly accelerating pace of discovery with record numbers of updates to our guidelines. Our work spans the spectrum from prevention and risk reduction through post-treatment survivorship and palliation, focused on ensuring that innovations are accessible for all. That is why we share strategies for ensuring delivery of high-quality, high-value, person-centered cancer care, whether it be standards of care or cutting-edge cancer research. We re-assert our commitment to meet every patient where they are and to treat the whole person. One size does not fit all in oncology—but the NCCN Guidelines and related resources provide everyone with tools to match the right treatment with the right person at the right time in order to get the best possible outcome.”

More than 1,500 medical professionals across all disciplines on oncology took part in the hybrid meeting in Orlando and online. There were more than 200 posters featuring original, high-impact research—curated by the NCCN Oncology Research Program (ORP) and now available as abstracts at JNCCN.org, the online home of JNCCN—Journal of the National Comprehensive Cancer Network. Fishbowl discussions provided opportunities for peer-to-peer brainstorming about current concerns in the oncology field, including staff burnout, diversity in clinical trial participation, and the implications of Artificial Intelligence (AI) in cancer care.

AI and Cancer Care

Tools and policies for AI were also the subject of one of the conference’s two main plenary sessions. Speakers highlighted ways that digital tools have potential to transform health care delivery for the better. They pointed out the ability of large language model (LLM) tools to track the accelerating pace of new knowledge at a rate the human brain cannot.

However, panelists also noted that AI will never be able to convey the sense that another human being cares, which has therapeutic benefits. They stated that AI-informed care should only occur when it is beneficial and transparent for everyone involved, with a focus on four major considerations:

  • Data and Curation Sharing
  • Bias and Fairness
  • Regulation and Evaluation
  • Integration into Clinical Workflow

“As AI becomes increasingly more powerful, it is critical that it maintains human values and has human oversight,” commented Dennis Chornenky, MBA, MPH, MS, CEO of Domelabs AI and former Chief AI Advisor at UC Davis Health.

Mental Health, Smoking Cessation, Stigma, and Cancer Care

A second plenary session dealt with the topic of mental health care for people with cancer. Speakers noted that those with the greatest needs for assistance tend to be the least likely to ask for it. They also pointed out that people whose social-emotional needs are addressed adhere better to treatment, are more likely to complete the full course of treatment, tend to have lower mortality rates, and have a higher likelihood of returning to work. There was also discussion regarding the mental health needs of caregivers. Panelists concluded that is it crucial to routinely ask all patients about their emotional wellbeing – not just at the onset of treatment but also during any transitions in care.

Additional sessions, such as one on navigating various stigmas and another on smoking cessation added to the conversation on how to ask patients the right questions and do so in a way that will build trust between them and their providers.

The smoking cessation panel called attention to the fact that only 15% of patients with cancer reported being counseled about quitting smoking, despite the fact that it dramatically improves outcomes, reduces long term effects, and can lower the risk for recurrence. Studies found that when providers did engage with their patients about smoking, they had double the rate of successfully breaking the addiction.

“Treating patients with cancer is clearly hard. They have a big mountain to climb. But we cannot avoid asking about smoking. It’s going to impact their survival. It’s going to impact the efficacy of treatment,” said Mary E. Reid, MSPH, PhD, Chief of Cancer Screening, Survivorship and Mentorship at Roswell Park Comprehensive Cancer Center, a Member of the NCCN Guidelines Panel for Lung Cancer Screening.

“Keep it short but make it happen,” agreed James M. Davis, MD, of the Duke Cancer Institute,  Director for Duke Center for Smoking Cessation, and Member of the NCCN Guidelines Panel for Smoking Cessation, who noted that much more advice for both patients and providers across the continuum of care can be found in recently-published NCCN Guidelines for Patients®: Quitting Smoking—available for free at NCCN.org/patientguidelines through funding from the NCCN Foundation®.

Clinical and Administrative Updates

The conference featured numerous practice-changing clinical updates from the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for treating various cancers, including colorectal, lung, prostate, multiple myeloma, mesothelioma, gastrointestinal, gynecologic, and head and neck cancers. Updates on hereditary and genetic risk across numerous cancer types were also presented. Speakers noted the importance of letting people with cancer know that there is an expectation of change over time; care teams are learning with them and will always do the best they can with the information they have at the time.

The conference provided audience members from various roles across the oncology care team with practical information for improving all aspects of cancer care delivery—particularly in the non-academic setting. Additional sessions focused on topics like oncology nursing, oncologic urgent care and dentistry, APPs in the outpatient setting, navigation models, and telehealth.

Save The Dates

The NCCN Annual Conference will return to the Caribe Royale Orlando on March 27March 29, 2026.

Before then, NCCN has several additional opportunities for Continuing Education and Policy learning, including:

  • NCCN Oncology Policy Summit: Primary Care and Oncology Collaboration to Improve Patient Outcomes in Washington D.C. at the National Press Club on May 6, 2025.
  • NCCN Oncology Policy Summit: The Evolving Artificial Intelligence Landscape in Cancer Care in Washington D.C. at the National Press Club on September 9, 2025.
  • NCCN 2025 Annual Congress: Hematologic Malignancies™ at the Hilton San Diego Bayfront, San Diego, California on October 10 – 11, 2025.

Visit NCCN.org for more information on events and resources that define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is marking 30 years as a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.

Media Contact:
Rachel Darwin
267-622-6624
darwin@nccn.org

NCCN Logo (C)NCCN(R) 2018. All rights reserved.
NCCN Logo (C)NCCN(R) 2018. All rights reserved.

 

Opsera Raises $20M to Drive AI-Powered DevOps Platform Innovation, Accelerating AI Agent Adoption and Developer Efficiency

Opsera reports 200% revenue growth since raising Series A+ and expands Unified Insights with AI code assistant integrations to improve developer experience.

SAN FRANCISCO, April 2, 2025 /PRNewswire/ — Opsera, the AI-Powered DevOps platform trusted by top Fortune 1000 companies, today announced it has raised $20M in Series B funding, led by Prosperity7 with participation from Hitachi Ventures. The funding culminates a breakout year with several product releases that position Opsera as one of the market’s most flexible and intelligent AI-powered DevOps platforms for all apps and teams. Significant accomplishments include signing key industry partnerships with GitHub, Microsoft, AWS, and Databricks, 200% revenue growth since raising Series A+, and adding several key Fortune 1000 customers.

Learn More About Opsera: https://www.opsera.io/

Empowering Developers with Agentic AI and Unified Insights

The DevOps industry is undergoing a seismic shift driven by AI-driven automation, security integration, and the need for rapid, reliable software delivery. Organizations now prioritize AI Agentic approaches — systems where autonomous AI agents optimize workflows, predict risks, and self-heal infrastructure — to stay competitive. Opsera is pioneering Agentic AI to reshape DevOps workflows, enabling software engineering teams to move beyond static automation toward adaptive, intelligent orchestration. Traditional DevOps automation focuses on predefined workflows, but Opsera’s AI-driven approach introduces autonomous AI agents that dynamically analyze, adapt and optimize software delivery in real-time.

These AI agents, embedded within Opsera’s AI-Powered DevOps platform, act as intelligent copilots that continuously monitor and enhance software delivery processes and the pipelines. By learning from developer interactions and activities, pipeline executions, release flows and operational bottlenecks, these agents proactively recommend optimizations, automate complex decision-making, and self-correct inefficiencies across the software delivery lifecycle.

“At Opsera, we are redefining what’s possible in DevOps with our AI-powered DevOps Platform for all teams, powered by Agentic AI, and the momentum we’re seeing is a direct reflection of the value we’re delivering to our customers,” said Kumar Chivukula, CEO of Opsera. “We are grateful to Prosperity7, Hitachi Ventures and existing investors (Clear Ventures, Felicis Ventures, Taiwania Capital, Alumni Ventures) for supporting our vision to empower organizations to achieve unprecedented agility, reliability, and automated security remediation in their DevSecOps pipelines. With Opsera Unified Insights, customers gain the deepest and most intuitive metrics across ‘Code to Cloud’ – Copilot, DevEx, DORA, Security, Quality, GitHub Advanced Security and more – to instrument the software development cycle and to improve developer productivity and experience significantly.”

“Opsera’s AI-powered DevOps platform has completely redefined how we approach DevOps,” said Brad Bell, CIO of Qualys. “Opsera has eliminated the friction of custom builds needed to support our complex SaaS platforms. What used to take weeks of manual effort now happens in hours, accelerating software delivery by 80% and unlocking new levels of productivity and agility. Simply put, Opsera empowers us to innovate faster and operate smarter.”

Opsera’s powerful AI-powered DevOps platform offers forward-leaning software development organizations a game-changing boost in developer productivity and global insights across the entire software lifecycle,” said Abhishek Shukla, Managing Director of Prosperity7. “Their partnerships with GitHub, Databricks and AWS are opening new use cases that will continue to drive accelerating growth, which was a very compelling story that gave us confidence to lead this Series B round.”

“Opsera has gone from strength to strength over the past four and a half years since our initial seed investment,” said Rajeev Madhavan, Managing Director of Clear Ventures. “Our original thesis that the DevOps category was ripe for modernization and consolidation has borne out. Opsera continues to innovate and add exciting functionality to its AI-powered DevOps Platform for All – including AI Agentic capabilities, global insights for Generative AI tools like GitHub Copilot, Amazon Q, and Cursor, as well as CI/CD orchestration for all apps and teams.”

“As demand for data intelligence grows, Opsera’s partnership with Databricks is helping bring simplicity and accelerated deployment cycles for clients embarking on AI and LLM deployments. The Built on Databricks partnership brings DevOps for DataOps and modernizes data manipulation and orchestration,” said Heather Akuiyibo, VP of GTM Integration at Databricks.

IDC research finds that on average, developers estimate a 35% increase in their productivity with the use of an AI coding assistant. However, it is challenging to have visibility into adoption and measure these gains across the organization,” said Katie Norton, Research Manager, DevSecOps at IDC. “The metrics available in Opsera’s Unified Insights should enable organizations to demonstrate the ROI of GitHub Copilot adoption, enhancing their ability to track and quantify productivity improvements.”

Recent Key Milestones Include:

  • Opsera AI Agents: Opsera’s Hummingbird AI transforms fragmented DevOps processes into a unified, AI-driven engine. By connecting insights from GitHub Copilot, Jira, VS code, cloud deployments, and security tools, the Opsera AI-powered DevOps Platform delivers proactive risk mitigation (e.g., blocking insecure code), end-to-end visibility (e.g., vulnerability-to-Jira mapping) and self-healing workflows (e.g., auto-patching OS images)
  • New Unified Insights Capabilities: Opsera’s AI Code Assistant Insights provides actionable intelligence on developer productivity, adoption trends, and the effectiveness of AI-driven code suggestions. Enterprises can proactively measure and optimize the ROI of their AI Code Assistant investments while improving developer experience and productivity across software delivery tools, teams, and environments.
  • Leadership Dashboard: As part of Opsera’s Unified Insights, the Leadership Dashboard offers granular, real-time visibility into inner-loop (software development) and outer-loop (software delivery) activities, AI adoption, and the impact of AI-powered tools like GitHub Copilot. Additionally, it delivers Developer Experience (DevEx) insights, DORA metrics, and application security posture insights—empowering leaders to enhance efficiency, innovation, velocity, security, and quality at scale. With these insights, organizations can streamline DevOps and DevSecOps processes, maximize AI-driven development efficiency, and drive continuous improvement across the SDLC.
  • Expanded Strategic Partnerships:
    • GitHub: Opsera deepened its relationship with GitHub, delivering SCM migration services and the most advanced insights and metrics for GitHub Copilot deployments as an ISV partner.
    • Databricks: Opsera joined Databricks’ Built on Partner Program and Technology Partner Program. Opsera and Databricks enable AI/ML model deployments with security and compliance guardrails and schema deployments with rollback capabilities.
    • AWS: Opsera was also accepted into the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. By combining Opsera’s orchestration capabilities with the power of Amazon Q, users can unlock a new level of efficiency and innovation in their AWS deployments.

Opsera empowers leaders to make data-driven decisions that enhance productivity and drive innovation across their teams by providing detailed insights into how developers interact with tools like Copilot. Learn More https://www.opsera.io/solutions/leadership-dashboard

About Opsera
Opsera is an AI-powered DevOps platform for all apps and teams. From comprehensive pipeline creation and management to a robust marketplace of pre-built integrations and complete analytic and reporting capabilities, organizations achieve faster release cycles, maintain and improve quality, and increase efficiency within their software development processes. Top Fortune 1000 companies are speeding up their time to market by building, testing, deploying, reporting, and monitoring their applications with Opsera’s leading DevOps platform.

Contact:
Olivia Heel
Catapult PR
oheel@catapultpr-ir.com